Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25748361 | 0.89 | HTR1A (0.46) | HTR6HTR1AHTR2A | |
| SCHEMBL25436824 | 0.89 | HTR6 (0.60) | HTR6HTR1AHTR2ACYP1A2CYP2D6 | |
| SCHEMBL25436799 | 0.85 | HTR1A (0.53) | HTR6HTR1AHTR2ACYP1A2CYP3A4 | |
| SCHEMBL25748357 | 0.84 | HTR6 (0.46) | HTR6HTR1AHTR2ACYP1A2CYP2D6 | |
| SCHEMBL25029582 | 0.84 | HTR1D (0.43) | HTR1AHTR2ASLC6A2 | |
| SCHEMBL25437580 | 0.83 | HTR6 (0.44) | HTR6HTR1AHTR2A | |
| SCHEMBL25435316 | 0.82 | HTR2A (0.56) | HTR6HTR2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25029867 | 0.81 | HTR1A (0.57) | HTR6HTR1AHTR2ASLC6A2 | |
| SCHEMBL24460209 | 0.80 | HTR2A (0.58) | HTR6HTR1AHTR2ACYP1A2BLM | |
| SCHEMBL25747860 | 0.80 | HTR1A (0.57) | HTR6HTR1AHTR2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| EP-4452937-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | HTR6 54/4885HTR1A 185/4885HTR2A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.